drug
FPI-2265
Phase 2updated 3mo agoby Fusion Pharmaceuticals Inc
Phase 2community read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying FPI-2265
- phase2Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
- phase2FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- phase2FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- phase2Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 22m ago
Found something off?
comments(0)
5-min edit window · permanent after that